BR0215048A - Composições farmacêuticas à base de derivados de azetidina - Google Patents
Composições farmacêuticas à base de derivados de azetidinaInfo
- Publication number
- BR0215048A BR0215048A BR0215048-4A BR0215048A BR0215048A BR 0215048 A BR0215048 A BR 0215048A BR 0215048 A BR0215048 A BR 0215048A BR 0215048 A BR0215048 A BR 0215048A
- Authority
- BR
- Brazil
- Prior art keywords
- azetidine
- pharmaceutical compositions
- formula
- derivatives
- azetidine derivative
- Prior art date
Links
- 150000001539 azetidines Chemical class 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical class C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000002708 enhancing effect Effects 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108050007331 Cannabinoid receptor Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000084 colloidal system Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 230000003381 solubilizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"COMPOSIçõES FARMACêUTICAS A BASE DE DERIVADOS DE AZETIDINA". A presente invenção refere-se a uma composição farmacêutica estável que compreende pelo menos um derivado de azetidina de fórmula geral (Ia) ou (Ib) na qual Ar é um grupamento aromático ou heteroaromático eventualmente substituído por um ou vários (C1-C4)alquila, halogênio, NO~ 2~, CN, (C1-C4) alcóxi ou OH, eventualmente em associação com um outro princípio ativo capaz de potencializar os efeitos do derivado de azetidina de fórmula geral (Ia) ou (Ib), em um sistema que compreende no máximo 2 excipientes principais escolhidos entre um agente tensoativo não-iónico de caráter hidrófilo capaz de solubilizar o derivado de azetidina de fórmula geral (Ia) ou (Ib) e se for o caso o princípio ativo que potencializa os efeitos do derivado de azetidina, e capaz de provocar a formação de um sistema coloidal, adicionado eventualmente de um segundo excipiente de natureza lipofílica, que estabiliza a formulação. As composições farmacêuticas que compreendem derivados de azetidina de fórmulas (Ia) ou (Ib) são especialmente interessantes devido à grande afinidade desses derivados para os receptores canabinóides.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0116638A FR2833842B1 (fr) | 2001-12-21 | 2001-12-21 | Compositions pharmaceutiques a base de derives d'azetidine |
| PCT/FR2002/004514 WO2003053431A2 (fr) | 2001-12-21 | 2002-12-20 | Compositions pharmaceutiques a base de derives d'azetidine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0215048A true BR0215048A (pt) | 2004-11-03 |
Family
ID=8870824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0215048-4A BR0215048A (pt) | 2001-12-21 | 2002-12-20 | Composições farmacêuticas à base de derivados de azetidina |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP1458413B1 (pt) |
| JP (1) | JP5021887B2 (pt) |
| KR (1) | KR20040068308A (pt) |
| CN (1) | CN100388918C (pt) |
| AP (1) | AP1754A (pt) |
| AR (1) | AR037687A1 (pt) |
| AU (1) | AU2002364866B2 (pt) |
| BR (1) | BR0215048A (pt) |
| CA (1) | CA2470443A1 (pt) |
| CO (1) | CO5590911A2 (pt) |
| DE (1) | DE60233071D1 (pt) |
| DK (1) | DK1458413T3 (pt) |
| EA (1) | EA006510B1 (pt) |
| EC (1) | ECSP045162A (pt) |
| FR (1) | FR2833842B1 (pt) |
| HR (1) | HRP20040575A2 (pt) |
| HU (1) | HUP0402586A3 (pt) |
| IL (1) | IL162563A0 (pt) |
| MA (1) | MA27086A1 (pt) |
| ME (1) | MEP16608A (pt) |
| MX (1) | MXPA04005558A (pt) |
| MY (1) | MY138172A (pt) |
| NO (1) | NO20042781L (pt) |
| NZ (1) | NZ533225A (pt) |
| OA (1) | OA12750A (pt) |
| PL (1) | PL203248B1 (pt) |
| RS (1) | RS55504A (pt) |
| TW (1) | TWI256304B (pt) |
| UA (1) | UA77736C2 (pt) |
| WO (1) | WO2003053431A2 (pt) |
| ZA (1) | ZA200404338B (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1498123A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Emulsifying systems containing azetidine derivatives |
| EP1498122A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Semi-solid systems containing azetidine derivatives |
| BRPI0507801A (pt) | 2004-02-17 | 2007-07-10 | Esteve Labor Dr | compostos de azetidina substituìda, processo para a preparação de compostos de azetidina substituìda, medicamento e uso de pelo menos um composto de azetidina substituìda |
| FR2879932B1 (fr) * | 2004-12-27 | 2007-03-23 | Aventis Pharma Sa | Formulations injectable ou administrable par voie orale de derives d'azetidine |
| KR20080027908A (ko) | 2005-06-30 | 2008-03-28 | 프로시디온 리미티드 | Ｇｐｃｒ 효능제 |
| HRP20110852T1 (hr) | 2007-01-04 | 2011-12-31 | Prosidion Limited | PIPERIDINSKI AGONISTI GPCR-a |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| JP2010514832A (ja) | 2007-01-04 | 2010-05-06 | プロシディオン・リミテッド | ピペリジンｇｐｃｒアゴニスト |
| AR064735A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
| CL2008000017A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| FR2923719B1 (fr) * | 2007-11-15 | 2009-11-20 | Sanofi Aventis | Compositions pharmaceutiques a base de derives d'azetidine |
| FR2928149B1 (fr) | 2008-02-29 | 2011-01-14 | Sanofi Aventis | Composes derives d'azetidines, leur preparation et leur application en therapeutique |
| FR2946650B1 (fr) * | 2009-06-16 | 2011-08-19 | Sanofi Aventis | Esters derives d'azetidines, leur preparation et leur application en therapeutique. |
| UA153183U (uk) | 2022-10-27 | 2023-05-31 | Андрій Валерійович Максимов | Стаканчик для приготування напою |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR73668B (pt) * | 1978-11-21 | 1984-03-28 | Hoffmann La Roche | |
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| HRP980026A2 (en) * | 1998-01-20 | 1999-10-31 | Pliva Pharm & Chem Works | 1-izothiazolydinone derivatives of azetidine-2-ones, processes for the preparation and use thereof |
| CN1273526A (zh) * | 1998-07-14 | 2000-11-15 | Em工业股份有限公司 | 微分散给药系统 |
| FR2783246B1 (fr) * | 1998-09-11 | 2000-11-17 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les medicaments les contenant |
| FR2805810B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
| FR2805817B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
| FR2805818B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
| FR2814678B1 (fr) * | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
-
2001
- 2001-12-21 FR FR0116638A patent/FR2833842B1/fr not_active Expired - Fee Related
-
2002
- 2002-12-02 AR ARP020104646A patent/AR037687A1/es unknown
- 2002-12-03 TW TW091135077A patent/TWI256304B/zh active
- 2002-12-20 PL PL372708A patent/PL203248B1/pl not_active IP Right Cessation
- 2002-12-20 ME MEP-166/08A patent/MEP16608A/xx unknown
- 2002-12-20 JP JP2003554188A patent/JP5021887B2/ja not_active Expired - Fee Related
- 2002-12-20 MY MYPI20024828A patent/MY138172A/en unknown
- 2002-12-20 KR KR10-2004-7009708A patent/KR20040068308A/ko not_active Ceased
- 2002-12-20 EA EA200400843A patent/EA006510B1/ru not_active IP Right Cessation
- 2002-12-20 HR HR20040575A patent/HRP20040575A2/hr not_active Application Discontinuation
- 2002-12-20 RS YUP-555/04A patent/RS55504A/sr unknown
- 2002-12-20 HU HU0402586A patent/HUP0402586A3/hu unknown
- 2002-12-20 CN CNB028248406A patent/CN100388918C/zh not_active Expired - Fee Related
- 2002-12-20 CA CA002470443A patent/CA2470443A1/fr not_active Abandoned
- 2002-12-20 BR BR0215048-4A patent/BR0215048A/pt not_active IP Right Cessation
- 2002-12-20 UA UA20040706001A patent/UA77736C2/uk unknown
- 2002-12-20 DE DE60233071T patent/DE60233071D1/de not_active Expired - Lifetime
- 2002-12-20 AU AU2002364866A patent/AU2002364866B2/en not_active Ceased
- 2002-12-20 IL IL16256302A patent/IL162563A0/xx unknown
- 2002-12-20 EP EP02801165A patent/EP1458413B1/fr not_active Expired - Lifetime
- 2002-12-20 DK DK02801165T patent/DK1458413T3/da active
- 2002-12-20 WO PCT/FR2002/004514 patent/WO2003053431A2/fr not_active Ceased
- 2002-12-20 AP APAP/P/2004/003066A patent/AP1754A/en active
- 2002-12-20 NZ NZ533225A patent/NZ533225A/en not_active IP Right Cessation
- 2002-12-20 MX MXPA04005558A patent/MXPA04005558A/es active IP Right Grant
- 2002-12-20 OA OA1200400178A patent/OA12750A/fr unknown
-
2004
- 2004-05-21 MA MA27694A patent/MA27086A1/fr unknown
- 2004-06-02 ZA ZA200404338A patent/ZA200404338B/en unknown
- 2004-06-17 CO CO04056913A patent/CO5590911A2/es not_active Application Discontinuation
- 2004-06-18 EC EC2004005162A patent/ECSP045162A/es unknown
- 2004-07-01 NO NO20042781A patent/NO20042781L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0215048A (pt) | Composições farmacêuticas à base de derivados de azetidina | |
| ECSP024323A (es) | Compuestos organicos | |
| BR0208103A (pt) | Composição para a prevenção de osteoporose compreendendo uma combinação de isoflavonas e ácidos graxos poliinsaturados | |
| BRPI0316532B8 (pt) | composições farmacêuticas compreendendo uma droga básica ou ácida, um tensoativo, e um ácido ou base solúvel em água fisiologicamente tolerável | |
| BRPI0416752A (pt) | composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica | |
| BR0111034A (pt) | Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou doenças inflamatórias, para o tratamento e/ou profilaxia de osteoporose e para o tratamento de doenças relacionadas à aids | |
| PT1073470E (pt) | Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos | |
| DE60104206D1 (de) | Halbfeste arzneizubereitung enthaltend isotretinoin | |
| BR0014285A (pt) | Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico | |
| ITRM20010356A1 (it) | "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina. | |
| NO20000466L (no) | Farmasøytisk preparat for sure, lipofile forbindelser i form av en selvregulerende formulering | |
| BR0109317A (pt) | Composições contendo componentes agonistas alfa-2-adrenérgicos | |
| MA27551A1 (fr) | Composition immunogene | |
| BR0307524A (pt) | Composição farmacêutica para inibidores de protease viral de hepatite c | |
| ATE538797T1 (de) | Pharmazeutische zusammensetzungen mit neuroaktivem steroid und verwendungen davon | |
| BR0210028A (pt) | Agentes antibacterianos | |
| BR0212386A (pt) | Composto, formulação farmacêutica, e, uso de um composto | |
| BR0215148A (pt) | Composições farmacêuticas de agonista parcial 5ht4 | |
| BRPI0417161A (pt) | compostos, composições farmacêuticas, e, uso de um composto | |
| BR0212353A (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| AR046226A1 (es) | Formulaciones farmaceuticas que contienen saborizante con caracteristicas farmaceuticas mejoradas | |
| BR0115026A (pt) | Composição agroquìmica | |
| BR0312817A (pt) | Composição de pomada oftálmica compreendendo uma droga, uma base de pomada e um agente solubilizante/dispersante | |
| BRPI0415936A (pt) | composição estabilizada de azitromicina | |
| BRPI0614197B8 (pt) | composição farmaceuticamente eficaz em uma forma farmacêutica para administração peroral contendo pelo menos um dos ingredientes ativos indometacina e acemetacina, formas de administração, e, uso da composição |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: PARA: INT. CL. A61K 47/14; A61P 25/00 Ipc: A61K 47/14 (2011.01), A61P 25/00 (2011.01) |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012. |